Highly attenuated Bordetella pertussis strain BPZE1 as a potential live vehicle for delivery of heterologous vaccine candidates

Infection and Immunity

Volumn 76, Issue 1, 2008, Pages 111-119

  Si, Ying Ho ^a   Shi, Qian Chua ^a   Foo, Damian G W ^a   Locht, Camille ^b,c   Chow, Vincent T ^a   Chit, Laa Poh ^a   Alonso, Sylvie ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b INSERM   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; CARRIER PROTEIN; HEMAGGLUTININ; LIVE VACCINE; PROTEIN BRKA; UNCLASSIFIED DRUG;

ANTIBODY TITER; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BORDETELLA PERTUSSIS; BORDETELLA PERTUSSIS BPZE1; CHIMERA; DRUG SAFETY; ENTEROVIRUS 71; HAND FOOT AND MOUTH DISEASE; IMAGE DISPLAY; NONHUMAN; NUCLEOTIDE SEQUENCE; PERTUSSIS; PRIORITY JOURNAL; STRAIN IDENTIFICATION; VACCINATION;

ADMINISTRATION, INTRANASAL; ANIMALS; B-LYMPHOCYTES; BACTERIAL OUTER MEMBRANE PROTEINS; BORDETELLA PERTUSSIS; CAPSID PROTEINS; ENTEROVIRUS A, HUMAN; GENE DELETION; LUNG; MICE; NUCLEOPROTEINS; VIRAL VACCINES;

EID: 37749026630     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.00795-07     Document Type: Article

References (62)

1. Alonso, S., K. Pethe, N. Mielcarek, D. Raze, and C. Locht. 2001. Role of ADP-ribosyltransferase activity of pertussis toxin in toxin-adhesin redundancy with filamentous hemagglutinin during Bordetella pertussis infection. Infect. Immun. 69:6038-6043.
2. Alonso, S., N. Reveneau, K. Pethe, and C. Locht. 2002. Eighty-kilodalton N-terminal moiety of Bordetella pertussis filamentous hemagglutinin: adherence, immunogenicity, and protective role. Infect. Immun. 70:4142-4147.
3. Alonso, S., E. Willery, G. Renauld-Mongenie, and C. Locht. 2005. Production of nontypeable Haemophilus influenzae HtrA by recombinant Bordetella pertussis with the use of filamentous hemagglutinin as a carrier. Infect. Immun. 73:4295-4301.
4. Amsbaugh, D. F., Z. M. Li, and R. D. Shahin. 1993. Long-lived respiratory immune response to filamentous hemagglutinin following Bordetella pertussis infection. Infect. Immun. 61:1447-1452.
5. Andrews, R., A. Herceq, and C. Roberts. 1997. Pertussis notifications in Australia, 1991 to 1997. Commun. Dis. Intell. 21:145-148.
6. Barnes, M. G., and A. A. Weiss. 2001. BrkA protein of Bordetella pertussis inhibits the classical pathway of complement after C1 deposition. Infect. Immun. 69:3067-3072.
7. Bolivar, F., R. L. Rodriguez, P. J. Greene, M. C. Betlach, H. L. Heynecker, and H. W. Boyer. 1977. Construction and characterization of new cloning vehicles. II. A multipurpose cloning system. Gene 2:95-113.
8. Cahill, E. S., D. T. O'Hagan, L. Illum, A. Barnard, K. H. G. Mills, and K. Redhead. 1995. Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous hemagglutinin in solution or incorporated in biodegradable microparticles. Vaccine 13:455-462.
9. Cainelli Gebara, V., L. Risoleo, A. Lopes, V. Ferreira, W. Quintilio, F. Lepine, W. Silva, and I. Raw. 2007. Adjuvant and immunogenic activities of the 73kDa N-terminal alpha-domain of BrkA autotransporter and Cpn60/60kDa chaperonin of Bordetella pertussis. Vaccine 25:621-629.
10. Cardosa, M. J., D. Perera, B. A. Brown, D. Cheon, H. M. Chan, K. P. Chan, H. Cho, and P. McMinn. 2003. Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region: comparative analysis of the VP1 and VP4 genes. Emerg. Infect. Dis. 9:461-468.
11. Celentano, L. P., M. Massari, D. Paramatti, S. Salmaso, and A. E. Tozzi. 2005. Resurgence of pertussis in Europe. Pediatr. Infect. Dis. J. 24:761-765.
12. Chan, K. P., K. T. Goh, C. Y. Chong, E. S. Teo, G. Lau, and A. E. Ling. 2003. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg. Infect. Dis. 9:78-85.
13. Chen, H. F., M. H. Chang, B. L. Chiang, and S. T. Jeng. 2006. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine 24:2944-2951.
14. Chiu, C. H., C. Chu, C. C. He, and T. Y. Lin. 2006. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect. 8:1671-1678.
15. Coppens, I., S. Alonso, R. Antoine, F. Jacob-Dubuisson, G. Renauld-Mongenie, E. Jacobs, and C. Locht. 2001. Production of Neisseria meningitidis transferrin-binding protein B by recombinant Bordetella pertussis. Infect. Immun. 69:5440-5446.
16. Coutte, L., S. Alonso, N. Reveneau, E. Willery, B. Quatannens, C. Locht, and F. Jacob-Dubuisson. 2003. Role of adhesin release for mucosal colonization by a bacterial pathogen. J. Exp. Med. 197:735-742.
17. De Serres, G., and B. Duval. 2005. Pertussis vaccination beyond childhood. Lancet 365:1015-1026.
18. Elder, K. D., and E. T. Harvill. 2004. Strain-dependent role of BrkA during Bordetella pertussis infection of the murine respiratory tract. Infect. Immun. 72:5919-5924.
19. Ewanowich, C. A., A. R. Melton, A. A. Weiss, R. K. Sherburne, and M. S. Peppler. 1989. Invasion of HeLa 229 cells by virulent Bordetella pertussis. Infect. Immun. 57:2698-2704.
20. Fernandez, R. C., and A. A. Weiss. 1994. Cloning and sequencing of a Bordetella pertussis serum resistance locus. Infect. Immun. 62:4727-4738.
21. Fernandez, R. C., and A. A. Weiss. 1996. Susceptibilities of Bordetella pertussis strains to antimicrobial peptides. Antimicrob. Agents Chemother. 40: 1041-1043.
22. Foo, G. W. D., S. Alonso, T. K. V. Chow, and C. L. Poh. 2007. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect. 9:1299-1306.
23. Foo, G. W. D., S. Alonso, M. C. Phoon, N. P. Ramachandran, T. K. V. Chow, and C. L. Poh. 2007. Identification of neutralizing linear epitopes from the VP1 capsid protein of enterovirus 71 using synthetic peptides. Virus Res. 125:61-68.
24. Guedin, S., E. Willery, C. Locht, and F. Jacob-Dubuisson. 1998. Evidence that a globular conformation is not compatible with FhaC-mediated secretion of the Bordetella pertussis filamentous haemagglutinin. Mol. Microbiol. 29:763-774.
25. Henderson, I. R., F. Navarro-Garcia, M. Desvaux, R. C. Fernandez, and D. Ala'Aldeen. 2004. Type V protein secretion pathway: the autotransporter story. Microbiol. Mol. Biol. Rev. 68:692-744.
26. Henderson, I. R., F. Navarro-Garcia, and J. P. Nataro. 1998. The great escape: structure and function of the autotransporter proteins. Trends Microbiol. 6:370-378.
27. Ho, M., E. R. Chen, K. H. Hsu, S. J. Twu, K. T. Chen, S. F. Tsai, J. R. Wang, and S. R. Shih. 1999. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N. Engl. J. Med. 341:929-935.
28. Ikemura, T. 1985. Codon usage and tRNA content in unicellular and multicellular organisms. Mol. Biol. Evol. 1:13-34.
29. Jacob-Dubuisson, F., C. Locht, and R. Antoine. 2001. Two-partner secretion in Gram-negative bacteria: a thrifty, specific pathway for large virulence proteins. Mol. Microbiol. 40:306-313.
30. Jain, S., P. van Ulsen, I. Benz, M. A. Schmidt, R. C. Fernandez, J. Tommassen, and M. B. Goldberg. 2006. Polar localization of the autotransporter family of large bacterial virulence proteins. Infect. Immun. 188:4841-4850.
31. Kramer, U., K. Rizos, H. Apfel, I. B. Autenrieth, and C. T. Lattermann. 2003. Autodisplay: development of an efficacious system for surface display of antigenic determinants in Salmonella vaccine strains. Infect. Immun. 71: 1944-1952.
32. Lattemann, C. T., J. Maurer, E. Gerland, and T. F. Meyer. 2000. Autodisplay: functional display of active β-lactamase on the surface of Escherichia coli by the AIDA-I autotransporter. J. Bacteriol. 182:3726-3733.
33. Locht, C. 2000. Live bacterial vectors for intranasal delivery of protective antigens. Pharm. Sci. Technol. Today 3:121-128.
34. Locht, C., P. Bertin, F. D. Menozzi, and G. Renauld. 1993. The filamentous hemagglutinin, a multifaceted adhesion produced by Bordetella spp. Mol. Microbiol. 9:653-660.
35. Mascart, F., V. Verscheure, A. Malfroot, M. Hainaut, D. Pierard, S. Temerman, A. Peltier, A.-S. Debrie, J. Levy, G. Del Giudice, and C. Locht. 2003. Bordetella pertussis infection in 2-months-old infants promotes type 1 T cell responses. J. Immunol. 170:1504-1509.
36. McMinn, P. C. 2002. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol. Rev. 26:91-107.
37. Menozzi, F. D., C. Gantiez, and C. Locht. 1991. Identification and purification of transferrin- and lactoferrin-binding proteins of Bordetella pertussis and Bordetella bronchiseptica. Infect. Immun. 59:3982-3988.
38. Mielcarek, N., S. Alonso, and C. Locht. 2001. Nasal vaccination using live bacterial vectors. Adv. Drug Deliv. Rev. 51:55-70.
39. Mielcarek, N., J. Cornette, A. Schacht, R. Pierce, C. Locht, A. Capron, and G. Riveau. 1997. Intranasal priming with recombinant Bordetella pertussis for the induction of a systemic immune response against a heterologous antigen. Infect. Immun. 65:544-550.
40. Mielcarek, N., A-S. Debrie, D. Raze, J. Bertout, C. Rouanet, A. B. Younes, C. Creusy, J. Engle, W. E. Goldman, and C. Locht. 2006. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathogens 2:0001-0009.
41. Mielcarek, N., I. Nordstrom, F. Menozzi, C. Locht, and J. Holmgren. 2000. Genital antibody responses in mice after intranasal infection with an attenuated candidate vector strain of Bordetella pertussis. Infect. Immun. 68:491-495.
42. Mielcarek, N., G. Riveau, F. Remoue, R. Antoine, A. Capron, and C. Locht. 1998. Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis. Nat. Biotechnol. 16:454-457.
43. Mooi, F. R., I. H. van Loo, and A. J. King. 2001. Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence? Emerg. Infect. Dis. 7:526-528.
44. Oliver, D. C., G. Huang, and R. C. Fernandez. 2003. Identification of secretion determinants of the Bordetella pertussis BrkA autotransporter. J. Bacteriol. 185:489-495.
45. Oliver, D. C., G. Huang, E. Nodel, S. Pleasance, and R. C. Fernandez. 2003. A conserved region within the Bordetella pertussis autotransporter BrkA is necessary for folding of its passenger domain. Mol. Microbiol. 47:1367-1383.
46. Palacios, G., and M. S. Oberste. 2005. Enterovirus as agent of emerging infectious diseases. J. Neurovirol. 11:424-433.
47. Poulain-Godefroy, O., F. D. Menozzi, S. Alonso, C., Vendeville, A. Capron, C. Locht, and G. Riveau. 2003. Adjuvant activity of free Bordetella pertussis filamentous hemagglutinin delivered by mucosal routes. Scand. J. Immunol. 58:503-510.
48. Quandt, J., and M. F. Hynes. 1993. Versatile suicide vectors which allow direct selection for replacement in Gram-negative bacteria. Gene 127:15-21.
49. Renauld-Mongenie, G., N. Mielcarek, J. Cornette, A.-M. Schacht, A. Capron, G. Riveau, and C. Locht. 1996. Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis. Proc. Natl. Acad. Sci. USA 93:7944-7949.
50. Reveneau, N., S. Alonso, F. Jacob-Dubuisson, A. Mercenier, and C. Locht. 2001. Tetanus toxin fragment C-specific priming by intranasal infection with recombinant Bordetella pertussis. Vaccine 20:926-933.
51. Roberts, G. B. S., and J. F. Boyd. 1987. The histopathology of enterovirus infections in new-born mice. J. Infect. 15:45-56.
52. Shahin, R., D. F. Amsbaugh, and M. F. Leef. 1992. Mucosal immunization with filamentous hemagglutinin protects against Bordetella pertussis respiratory infection. Infect. Immun. 60:1482-1488.
53. Shannon, J. L., and R. C. Fernandez. 1999. The C-terminal domain of the Bordetella pertussis autotransporter BrkA forms a pore in lipid bilayer membranes. J. Bacteriol. 181:5838-5842.
54. Siegrist, C. A. 2001. Neonatal and early life vaccinology. Vaccine 19:3331-3346.
55. Sivasamugham, L. A., M. J. Cardosa, W. S. Tan, and K. Yusoff. 2006. Recombinant Newcastle disease virus capsids displaying enterovirus 71 VP1 fragment induce a strong immune response in rabbits. J. Med. Virol. 78: 1096-1104.
56. Stibitz, S. 1994. Use of conditionally counterselectable suicide vectors for allelic exchange. Methods Enzymol. 235:458-465.
57. Tan, C. S., and M. J. Cardosa. 2007. High-titer neutralizing antibodies to human enterovirus 71 preferentially bind to the N-terminal portion of the capsid protein VP1. Arch. Virol. 157:1069-1073.
58. Veiga, E., V. De Lorenzo, and L. A. Fernandez. 2004. Structural tolerance of bacterial autotransporters for folded passenger protein domains. Mol. Microbiol. 52:1069-1080.
59. Wu, C. N., Y. C. Lin, C. Fann, N. S. Liao, S. R. Shih, and M. S. Ho. 2001. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20: 895-904.
60. Yanisch-Perron, C., J. Vieira, and J. Messing. 1985. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene 33:103-119.
61. Yu, C. K., C. C. Chen, C. L. Chen, J. R. Wang, C. C. Liu, J. J. Yan, and I. J. Su. 2000. Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J. Biomed. Sci. 7:523-528.
62. Zhu, C., F. Ruiz-Perez, Z. Yang, Y. Mao, V. L. Hackethal, K. M. Greco, W. Choy, K. Davis, J. R. Butterton, and E. C. Boedeker. 2006. Delivery of heterologous protein antigens via hemolysin or autotransporter systems by an attenuated ler mutant of rabbit enteropathogenic Escherichia coli. Vaccine 24:3821-3831.